# Age: A Moderating Effect on Cerebrospinal Fluid Fibroblast Growth Factor 21 and Cognitive Function

**Authors:** Ligang Shan, Ying Tao, Jiubo Fan, Yuyu Zhou, Danyang Zhao, Yanlong Liu, Xiaoli Han, Suriyakala Perumal Chandran, Fan Wang

PMC · DOI: 10.1002/brb3.70784 · Brain and Behavior · 2025-08-12

## TL;DR

This study finds that age influences how cerebrospinal fluid FGF21 affects cognitive function, with different effects in younger and older individuals.

## Contribution

It is the first study to report that age moderates the relationship between CSF FGF21 and cognition.

## Key findings

- Age moderates the relationship between CSF FGF21 and cognitive scores (R2 = 0.12, β = -0.32, p = 0.003).
- Higher CSF FGF21 levels protect cognition in individuals aged ≤34 years but may correlate with cognitive decline in those aged >34 years.

## Abstract

Fibroblast growth factors(FGF)19 subclass related to endocrine metabolism, including FGF19, FGF21, and FGF23, which is associated with cognition. Age can affect its secretion and has been identified as a significant risk factor for cognitive decline. Consequently, age may moderate the impact of the FGF19 subclass on cognitive function. This study aimed to investigate the association among the FGF19 subclass in cerebrospinal fluid (CSF), cognition, and age and further explore the moderating effects of age on cognitive changes related to the FGF19 subclass.

In this cross‐sectional study, participants were stratified into two groups based on age, namely the ≤34 year old (n = 128) and >34 year old (n = 63) groups, and CSF FGF19 subclass levels were measured. Cognition was assessed using the Montreal Cognitive Assessment Scores.

Age may play a moderating effect in the relationship between CSF FGF21 and cognition (R2 = 0.12, β = ‐0.32, p  = 0.003). In individuals aged >34 years old, a negative correlation was observed between serum TG levels and MoCA scores (r = ‐0.31, p = .041). Contrastingly, no correlation was noted between CSF FGF19 and CSF FGF23 levels with MoCA scores in both groups, respectively (all p > 0.05).

This is the first study to report that age plays a moderating effect in the relationship between CSF FGF21 and cognition. Moreover, higher CSF FGF21 levels have a protective effect on cognition in individuals aged ≤34 years old. However, individuals aged>34 years old can improve cognition via alternative strategies.

The effects of CSF FGF21 on cognition differ based on age, as evidenced by higher CSF FGF21 levels only exerting protective effects on cognition in males aged ≤34 years old. On the contrary, there was a trend toward cognitive decline with high CSF FGF21 levels in individuals aged >34 years old.

## Linked entities

- **Proteins:** FGF19 (fibroblast growth factor 19), FGF21 (fibroblast growth factor 21), FGF23 (fibroblast growth factor 23)

## Full-text entities

- **Genes:** FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], FGF19 (fibroblast growth factor 19) [NCBI Gene 9965], FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}
- **Diseases:** cognitive decline (MESH:D003072)
- **Chemicals:** TG (MESH:D013866)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12340712/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12340712/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12340712/full.md

---
Source: https://tomesphere.com/paper/PMC12340712